MOSB and National Cancer Centre Singapore sign MoU
A Memorandum of Understanding (MoU) has been signed between the Medical Oncology Society in Bangladesh (MOSB) and the National Cancer Centre Singapore, a subsidiary of SingHealth, to enhance collaboration and promote skill development through knowledge exchange.
The MoU, aimed at advancing lung cancer management, was formalised on 26 July 2025 at the BRAC Centre Auditorium in Mohakhali, Dhaka. Following the signing ceremony, a full-day workshop titled "Recent Updates on Evidence-Based Lung Cancer Management" was organised under the auspices of MOSB, with support from the National Cancer Centre Singapore and scientific partner Renata PLC.
The programme commenced with an address by Professor Dr Parveen Shahida Akhtar, President of the Medical Oncology Society in Bangladesh, who briefed attendees on the significance of the MoU. She highlighted that this agreement marks a significant step forward in advancing cancer treatment through mutual cooperation and knowledge exchange.
Keep updated, follow The Business Standard's Google news channel
The workshop attracted participation from both young and senior medical oncologists, aiming to share the latest developments in lung cancer diagnosis and treatment. During the event, Dr Tan Wei Chong, a distinguished international expert from the National Cancer Centre Singapore, delivered an engaging presentation on the latest advancements and evidence-based practices in lung cancer management. His talk, which offered practical insights supported by relevant data, was followed by a lively question-and-answer session, where physicians expressed their appreciation for his comprehensive and insightful discussion.
Certificates of Attendance were presented to all participating doctors in recognition of their commitment to ongoing professional development.
This collaboration marks a significant milestone in strengthening the partnership between Bangladesh and Singapore in the fight against lung cancer. The organisers are hopeful that this initiative will pave the way for further joint research, regular exchange programmes, collaborative clinical trials, and the development of shared training modules, ultimately aiming to enhance knowledge exchange and improve patient care.
